| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Mouse |
| Target | MUC1 |
| Clinical data | |
| Trade names | Theragyn |
| Routes of administration | Intraperitoneal |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| (what is this?) (verify) | |
Pemtumomab (trade name Theragyn) is a mouse monoclonal antibody used to treat cancer. The substance has affinity to various types of cancer, like ovarian cancer and peritoneal cancer, via the polymorphic epithelial mucin (PEM or MUC-1) and delivers the radioisotope Yttrium-90 into the tumour. As of 2009, it is undergoing Phase III clinical trials.
It has been granted orphan drug status in Europe.
References
- Oei AL, Moreno M, Verheijen RH, Sweep FC, Thomas CM, Massuger LF, von Mensdorff-Pouilly S (October 2008). "Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer". International Journal of Cancer. 123 (8): 1848–53. doi:10.1002/ijc.23725. PMID 18661524. S2CID 2287723.
- Clinical trial number NCT00004115 for "Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy" at ClinicalTrials.gov
- Antisoma's Lead Product, Pemtumomab Granted European Orphan Drug Status
 | This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it. |